We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The issue of who is vulnerable and what constitutes vulnerable populations in clinical trials has become increasingly complicated over time, and sponsors must consider a broader range of issues than they have in the past, experts say.